AXIM Biotechnologies

Company snapshot

AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical, and cosmetic products as well as alternative energy sources. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe in setting the green standard for cannabinoid bioscience through the discovery and commercializati

• 5 approved product(s) across US/EU regulatory metadata.
• 20 active pipeline program(s) linked via ClinicalTrials.gov.
• 138 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for AXIM Biotechnologies. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for AXIM Biotechnologies.

1. Jun 8, 2026 Clinical update

   PS22PET — Phase 2

2. Jun 8, 2026 Clinical update

   INFLUENCE — Phase 3

3. Jun 8, 2026 Clinical update

   IVEMEND for Delayed chemotherapy induced na… — Phase 3

4. Jun 8, 2026 Clinical update

   Ziftomenib for Acute Myeloid Leukemia, Mixed P… — Phase 1

5. Jun 8, 2026 Clinical update

   SP_MH20VYX — Phase 1

View all clinical trial activity →

• What is AXIM Biotechnologies?

  AXIM Biotechnologies is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker AXIM. Primary therapeutic focus areas include Neuroblastoma, Hyperinflammation, Sepsis, craniopharyngioma, Delayed chemotherapy induced nausea and vomiting (CINV), B-cell

• Is AXIM Biotechnologies publicly traded?

  Yes. AXIM Biotechnologies is listed with ticker AXIM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does AXIM Biotechnologies develop or market?

  We link 52 drug profile(s) where AXIM Biotechnologies is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/axim-biotechnologies-inc#company-drugs.

• What are the latest developments for AXIM Biotechnologies?

  In the last 12 months our linked public records show 20 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does AXIM Biotechnologies focus on?

  AXIM Biotechnologies focuses on Neuroblastoma, Hyperinflammation, Sepsis, craniopharyngioma based on our analysis of their pipeline programs and drug development activities.